Primary hyperparathyroidism and the skeleton
Tóm tắt
Today, primary hyperparathyroidism (PHPT) in the developed countries is typically a disease with few or no obvious clinical symptoms. However, even in the asymptomatic cases the endogenous excess of PTH increases bone turnover leading to an insidious reversible loss of cortical and trabecular bone because of an expansion of the remodelling space and an irreversible loss of cortical bone due to increased endocortical resorption. In contrast trabecular bone structure and integrity to a large extent is maintained and there may be a slight periosteal expansion. Most studies have reported decreased bone mineral density (BMD) in PHPT mainly located at cortical sites, whereas sites rich in trabecular bone only show a modest reduction or even a slight increase in BMD. The frequent occurrence of vitamin D insufficiency and deficiency in PHPT and increased plasma FGF23 levels may also contribute to the decrease in BMD. The effect of smoking is unsolved. Epidemiological studies have shown that the relative risk of spine and nonspine fractures is increased in untreated PHPT starting up to 10 years before the diagnosis is made. Successful surgery for PHPT normalizes bone turnover, increases BMD and decreases fracture risk based on larger epidemiological studies. However, 10 years after surgery fracture risk appears to increase again due to an increase in forearm fractures.
There are no randomized controlled studies (RCTs) demonstrating a protective effect of medical treatment on fracture risk in PHPT. Less conclusive studies suggest that vitamin D supplementation may have a beneficial effect on plasma PTH and BMD in vitamin D deficient PHPT patients. Hormone replacement therapy (HRT) and maybe SERM appear to reduce bone turnover and increase BMD. However, their nonskeletal side‐effects preclude their use for this purpose. Bisphosphonates reduce bone turnover and increase BMD in PHPT as in osteoporosis and may be a therapeutical option in selected patients with low BMD. Obviously, there is a need for larger RCTs with fractures as end‐points that appraise this possibility. Calcimimetics reduce plasma calcium and PTH in PHPT but has no beneficial effect on bone turnover or BMD. In symptomatic hypercalcaemic PHPT with low BMD where curative surgery is impossible or contraindicated a combination of a calcimimetic and a bisphosphonate may be an undocumented therapeutical option that needs further evaluation.
Từ khóa
Tài liệu tham khảo
Arnold A., 2002, Molecular pathogenesis of primary hyperparathyroidism, Journal of Bone and Mineral Research, 17, N30
Adami S., 2002, Epidemiology of primary hyperparathyroidism in Europe, Journal of Bone and Mineral Research Supplement, 2, N18
Moosgaard B., 2006, Plasma 1,25‐dihydroxyvitamin D levels in primary hyperparathyroidism depend on sex, body mass index, plasma phosphate and renal function, Clinical Endocrinology, 66, 35, 10.1111/j.1365-2265.2006.02680.x
Neer R.M., 2001, Effect of parathyroid hormone (1–34) on fracture and bone mineral density in postmenopausal women with osteoporosis, New England Journal of Medicine, 350, 459
Nissenson R.A., 2001, The Parathyroids. Basic and Clinical Concepts, 93
Melsen F., 1978, A tetracycline based evaluation of bone resorption and bone turnover in hyperthyroidism and hyperparathyroidism, Acta Medica Scandinavica, 204, 97, 10.1111/j.0954-6820.1978.tb08406.x
Charon S.A., 1982, Effects of parathyroid hormone on remodeling of iliac trabecular bone packets in patients with primary hyperparathyroidism, Clinical Orthopaedics and Related Research, 162, 255
Broulick P., 1982, Osteon cross‐sectional size in the iliac crest: variation in normals and patients with osteoporosis, hyperparathyroidism, acromegaly, hypothyroidism and treated epilepsy, Acta Pathologica, Microbiologica et Immunologica Scandinavica A, 190, 339, 10.1111/j.1699-0463.1982.tb00104_90A.x
Eriksen E.F., 2002, Primary hyperparathyroidism: lessons from bone histomorphometry, Journal of Bone and Mineral Research, 17, N95
Bilezikian J.P., 1991, Characterization and evaluation of asymptomatic primary hyperparathyroidism, Journal of Bone and Mineral Research, 6, S85
Rao D.S., 2002, Role of vitamin D and calcium nutrition in disease expression and parathyroid tumour growth in primary hyperparathyroidism: a global perspective, Journal of Bone and Mineral Research, 17, N75
Frost H.M., 1965, A synchronous group of mammalian cells, whose in vivo behaviour can be studied, Henry Ford Medical Bulletin, 13, 161
Frost H.M., 1964, Charles C Thomas
Moosgaard B. Christensen S.E. Vestergaard P. Heickendorff L. Christiansen P.&Mosekilde L.(2007)Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism.Clinical Endocrinology 2007 November 2; [Epub ahead of print].
Moosgaard B., 2006, Plasma 25‐hydroxyvitamin D and not 1,25‐dihydroxyvitamin D is associated with parathyroid adenoma secretion in primary hyperparathyroidism: a cross‐sectional study, Clinical Endocrinology, 155, 237
Hosoi J., 1985, Regulation of melanin synthesis of B16 mouse melanoma cells by 1α,25‐dihydroxyvitamin D3 and retinoic acid, Cancer Research, 45, 1474
Thakker R.V., 1986, Circulating concentrations of 1,25‐dihydroxyvitamin D3 in patients with primary hyperparathyroidism, Bone and Mineral, 1, 137
Frølich A., 1996, Does the plasma concentration of 25‐hydroxyvitamin D determine the level of 1,25‐dihydroxyvitamin D in primary hyperparathyroidism, Mineral and Electrolyte Metabolism, 22, 203
Jorde R., 2004, Serum parathyroid hormone levels in smokers and non‐smokers. The fifth Tromso study, European Journal of Endocrinology, 152, 1
Peacock M., 1984, Osteoporosis, 463
Lumachi F. Camozzi V. Ermani H. Nardi A.&Luisetto G.(2007)Lumbar spine bone mineral density changes in patients with primary hyperparathyroidism according to age and gender.Annals of the New York Academy of Sciences July 26 [Epub ahead of print].
Lumachi F. Camozzi V. Ermani H. De Lotto F.&Luisetto G.(2007)Bone mineral density improvement after successful parathyroidectomy in pre‐ and postmenopausal women with primary hyperparathyroidism. A prospective study.Annals of the New York Academy of Sciences July 23 [Epub ahead of print].
Silverberg S.J. Rubin M.R. Faiman C. Peacock M. Shoback D.M. Smallridge R.C. Schwanauer L.E. Olson K.A. Klassen P.&Bilezikian J.P.(2007)Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma.Journal of Clinical Endocrinology and Metabolism July 31; [Epub ahead of print].
Gallagher J.C., 1973, The effect of ethinylestradiol on calcium and phosphorus metabolism of postmenopausal women with primary hyperparathyroidism, Clinical Science and Molecular Medicine, 45, 785
Haldimann B., 1982, Hyperparathyroidie Primaire de la femme agee: effect des oestrogenes sur le metabolism calcique, Schweizeriche Medizinische Wochenschrift, 112, 1242
Marcus R., 2002, The role of estrogens and related compounds in the management of primary hyperparathyroidism, Journal of Bone and Mineral Research, 17, N146
Delmas P.D., 2002, Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four‐year results from a randomized clinical trial, Journal of Clinical Endocrinology and Metabolism, 87, 3609, 10.1210/jcem.87.8.8750
Misiorowski W., 2005, Alendronate increases bone mineral density in patients with symptomatic primary hyperparathyroidism, Endokrynologia Polska, 56, 871